Diagnostics in the Asia-Pacific region are becoming less invasive, more accessible, and more precise – so we can give patients the answers they need earlier.
In a region as vast and varied as the Asia-Pacific, healthcare can’t be one size fits all. From remote communities in Indonesia to ageing populations in Japan, the challenges facing patients and healthcare systems are as diverse as the region itself.
But there are three mounting pressures our health systems all share: rising disease burden, overstretched workforces, and persistent barriers to timely diagnosis. All of which result in delayed intervention. And when time is lost at the beginning of the care pathway, the impact is often felt at every step that follows.
The numbers show the scale of the challenge facing our region. Cancer is now the leading cause of death in many Asia-Pacific economies, with the region accounting for nearly half of all new cancer cases globally.1
Neurological conditions, including Alzheimer’s disease, are on the rise as populations age rapidly. Asia is home to the majority of the world’s people living with dementia, and that burden is projected to grow significantly in the decades ahead.2
Cardiovascular and metabolic diseases like diabetes, meanwhile, are placing enormous strain on patients, families, and health systems across the region. The Western Pacific alone – defined by the International Diabetes Federation as including East Asia, South East Asia and Oceana – is home to approximately 215 million people living with diabetes, the highest regional total in the world.3
The only way to reduce the burden of these chronic diseases is to detect them earlier – so we can give patients the right care, at the right time. It’s how we shift from reactive treatment to proactive prevention at regional scale, delivering genuinely personalised medicine for the people who need it most.
And on the horizon there’s hope – because new diagnostic technologies are helping us do just that. They’re transforming the patient journey by reducing barriers to care, offering quicker, more accurate information, and bringing diagnostics closer to the point of need.
1. HPV self-collection: Bringing cervical cancer screening to more women
Cervical cancer is one of the most preventable cancers. It’s the only cancer we’re likely to eliminate in our lifetimes. Yet in the Asia-Pacific region, prevention policies aren’t working. China and India alone account for around 39% of global cervical cancer deaths; the burden falls disproportionately on lower-resource communities where access to clinical screening is limited.1
The barriers to screening are significant; many women face long journeys to reach a clinic. Invasion of her privacy can give her unbearable anxiety. Cultural stigma around reproductive health is, in many communities, deeply embedded. In the face of these challenges many women, understandably, choose not to access testing. The result is a persistent gap between the number of women who need to be screened and the number who actually are.
HPV self-collection addresses these barriers directly. Women can collect their own vaginal sample – privately, comfortably, and without travelling to visit a specialist. Samples can be collected at a community health post, a pharmacy, or at home, before being sent to a laboratory for processing.
By separating sample collection from laboratory processing, HPV self-collection can extend the reach of screening programmes to communities that have historically been difficult to reach. And crucially, self-collected samples have been shown to offer comparable accuracy to those taken by a clinician.4
2. Blood-based biomarkers for Alzheimer’s disease: Earlier answers, without invasive procedures
The growing prevalence of Alzheimer’s disease will be one of the defining challenges for Asia-Pacific health systems. Our response will determine quality of life for tens of millions of older people.
Between 1990 and 2021, the prevalence of Alzheimer’s disease and other dementias in Asia soared by 250%. Mortality has risen by nearly 300%. DALYs (Disability-Adjusted Life-Years — years lived with disability + years of life lost) have risen by 250%.5
As life expectancy rises across our region, that burden will only grow.2 And by the middle of the century, more than half of the total number of people with dementia worldwide will live in the Asia Pacific region.2
Historically, confirming Alzheimer’s required costly, invasive procedures. PET imaging or lumbar punctures are available only in tertiary hospital settings and largely inaccessible to patients outside major urban centres.
But blood-based biomarker tests are changing this. By detecting biological markers of Alzheimer’s disease through a simple blood draw, these tests offer a far less invasive route to early diagnosis. They can be administered at primary care level, opening the door to earlier intervention – when it matters most.
Early diagnosis also changes the economics of care. The global economic burden of Alzheimer’s disease and related dementias is projected to reach USD 8.5 trillion by 2040.6 For Asia-Pacific health systems already under pressure from ageing demographics, the ability to identify the disease years before symptoms fully present – outside of specialist settings – represents a significant opportunity.
3. Portable, multi-test Point of Care platforms: Decentralising diagnostics for underserved communities
Point of Care Testing (POCT) is not a new concept. But the latest generation of portable, multi-test platforms are a major step change. Advances in miniaturisation have produced compact, easy-to-use devices capable of running a broad range of tests – from cardiovascular biomarkers and blood glucose to coagulation and inflammatory markers – from a single finger prick or swab7.
These platforms are particularly relevant for the Asia-Pacific region’s most underserved communities. Tests that once required centralised facilities and trained laboratory staff can now be performed at a rural health clinic, a community pharmacy, or a mobile health unit.
Rather than travelling for hours to access diagnostic services, waiting days for results, and making repeat visits to follow up, patients can receive accurate, actionable results in decentralised settings within minutes.
For Asia-Pacific health systems, frontloading diagnostics at the community level shifts economic burden away from more costly secondary and emergency care – reducing hospitalisation rates and follow-up visits for conditions that can be identified and managed earlier in the pathway.
In a region where around half the global population still has little or no access to diagnostics, rising to 81% in lower-middle income countries (LMICs), portable multi-test POCT platforms are one of the most practical levers available to close the diagnostic gap.8
4. AI-enabled predictive continuous glucose monitoring: Transforming diabetes management
Diabetes affects more people in the Western Pacific region than anywhere else in the world. The burden is growing.3 And for the many millions of people living with diabetes in our region, managing their condition is a demanding, relentless, lifelong challenge.
Effective diabetes management requires not only access to medication, but consistently accurate, timely information about blood glucose levels. Conventional glucose monitoring has a key limitation: it can only tell people living with diabetes where their glucose levels are right now.
But AI-enabled predictive continuous glucose monitoring (CGM) tells them where their levels are heading – so they can act before an episode of dangerous hypoglycaemia occurs, rather than responding to one that has already happened9.
The practical difference in patients’ daily lives and general wellbeing is enormous. One of the most debilitating anxieties for people living with diabetes is nighttime hypoglycaemia – dangerous drops in blood sugar during sleep that can have fatal consequences.
The fear of such an incident creates sustained anxiety, disrupted sleep, and mental burden before any episode occurs10. AI-enabled predictive CGM allows users to prevent nighttime hypoglycaemia by predicting lows before they go to bed, so they can take appropriate action, get a better night’s sleep and better manage their health11.
The economic case is just as compelling. Diabetes-related health expenditure is projected to reach USD 1.03 trillion globally by 2030.3 Technologies that support better glycaemic control – and thereby reduce costly complications and emergency admissions – carry clear system-level value.
5. Automated and standardised mass spectrometry: Precision at scale for complex conditions
The WHO’s most recent global transplant report shows that 19% of all solid organ transplants worldwide took place in the Western Pacific region, and a further 12% in South-East Asia – meaning nearly a third of global transplant activity now occurs in the Asia-Pacific region.12
For patients with conditions that require highly precise drug monitoring – like those who have undergone organ transplants – diagnostic accuracy is the difference between appropriate drug dosing and life-threatening toxicity. Getting the dose wrong could also lead to rejection of the organ.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for the therapeutic drug monitoring of immunosuppressants in transplant patients. With superior analytical specificity and sensitivity, it’s uniquely suited to detecting the narrow margins that determine safe and effective dosing.
But until recently, its application has been limited by the complexity of the equipment, the need for specialist operators, and significant variation in results across different laboratory settings.
Now, fully automated, standardised mass spectrometry is solving those problems. By automating the analytical process and standardising results across care centres, next-gen mass spectrometry extends the benefits of gold-standard precision diagnostics beyond specialist referral centres into a broader range of clinical settings.
We can only tackle chronic disease if we meet patients where they are
Addressing cancer, neurological conditions, cardiovascular and metabolic diseases all require diagnostic innovations that can reach more people, deliver faster results, and detect disease earlier.
And all five of these innovations show that the direction of travel is clear. Diagnostics in the Asia-Pacific region are becoming less invasive, more accessible, and more precise. They’re moving from hospital-centred models toward decentralised networks that meet patients where they are.
In the face of a growing disease burden and ever-growing pressure on our health systems, they can’t come soon enough.
Please note: Not all diagnostic innovations mentioned are available in every Asia-Pacific economy. Please help us raise awareness of the diagnostic innovations helping patients live happier, healthier lives, by sharing or reposting this article. Thank you.
